Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Nektar TherapeuticsNASDAQ: NKTR
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 385.4% from a year ago
Short-term investments stood at $645.23M at the end of Q2 FY2026, up 385.4% from a year earlier and up 47.7% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.
Context
- Short-term investments amounted to 58.9% of total assets at the end of Q2 FY2026, down 5.1 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +385.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 230.64M USD
- Year-over-year change
- +9.3%
- 4-year CAGR
- -24.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 230.64M | +9.3% |
| FY2024 | 2024-12-31 | 210.97M | -21.4% |
| FY2023 | 2023-12-31 | 268.34M | -35.6% |
| FY2022 | 2022-12-31 | 416.75M | -41.2% |
| FY2021 | 2021-12-31 | 708.74M | — |
Short-term Investments vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +385.4% is the 3rd highest of 10, against a peer median of +3.1%.
- Short-term investments amounts to 58.9% of total assets for NKTR, versus a peer median of 38.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $645.23M USD | +385.4% | -17.9% | 58.9% | |
| Jun 2026 | $552M USD | -16.7% | -1.9% | 59.7% | |
| Jun 2026 | $411.79M USD | +3.1% | -4.6% | 56.8% | |
| Mar 2026 | $392.22M USD | +8.9% | — | 36.6% | |
| Mar 2026 | $196.61M USD | +401.4% | +21.4% | 77.7% | |
| Mar 2026 | €152.4M EUR | -49.4% | -16.7% | 28.0% | |
| Mar 2026 | $122.51M USD | +37.4% | -8.7% | 84.0% | |
| Mar 2026 | $87.71M USD | +923.4% | +42.9% | 40.3% | |
| Mar 2026 | $51.81M USD | — | -13.4% | 19.5% | |
| Dec 2025 | €6.22M EUR | -56.8% | -28.9% | 9.9% | |
| Dec 2025 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding NKTR) | — | +3.1% | -6.7% | 38.4% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M |
| Short-term Investments | 708.74M | 416.75M | 268.34M | 210.97M | 230.64M |
| Net Receivables | 22.49M | 8.4M | 2.25M | 1.61M | 1.78M |
| Inventory | 15.8M | 19.2M | 16.1M | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 795.58M | 545.97M | 330.7M | 261.29M | 266.27M |
| Property, Plant & Equipment (Net) | 177.54M | 85.89M | 36.86M | 11.82M | 5M |
| Goodwill | 76.5M | 76.5M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 64.83M | 0 | 25.83M | 26.09M | 3.49M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.74M | 2.25M | 4.64M | 4.65M | 5.65M |
| Total Non-current Assets | 321.61M | 164.63M | 67.33M | 42.56M | 14.14M |
| Total Assets | 1.12B | 710.6M | 398.03M | 303.85M | 280.41M |
| Account Payables | 9.75M | 12.98M | 9.85M | 11.56M | 10.77M |
| Short-term Debt | 0 | 0 | 0 | 0 | 20.5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.74M | 9.58M | 5.55M | 5.55M | 22.27M |
| Total Current Liabilities | 85.2M | 68.2M | 51.27M | 61.4M | 53.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 63.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 226.75M | 162.93M | 117.26M | 99.02M | 8.63M |
| Total Non-current Liabilities | 352.48M | 275.76M | 215.78M | 181.71M | 137.04M |
| Total Liabilities | 437.68M | 343.96M | 267.05M | 243.11M | 190.57M |
| Common Stock | 19K | 19K | 19K | 19K | 2K |
| Retained Earnings | (2.83B) | (3.2B) | (3.48B) | (3.6B) | (3.76B) |
| Accumulated OCI | (4.16M) | (6.91M) | 80K | 61K | 17K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M |
| Total Debt | 143.18M | 131.5M | 117.78M | 102.56M | 148.91M |
| Net Debt | 117.96M | 43.27M | 82.5M | 58.31M | 133.79M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.